Illumina Sends Third Letter Asking Shareholders to Reject Roche Bid, Roche Disappointed by Illumina's Continued Rebuff | GenomeWeb

NEW YORK (GenomeWeb News) — Illumina today sent a third letter to shareholders urging them to turn away Roche's hostile bid for the company. At the same time, Roche expressed disappointment in Illumina's rebuff of its increased offer last week.

Illumina's annual shareholder meeting is scheduled for April 18, during which stockholders will elect four board members and vote on a proposal by Roche to expand the board by two members. Roche has named its own candidates for all open board positions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.